TARS Q2 2021 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M

Gross Profit

$21M96.7% margin

Operating Income

$7M33.1% margin

Net Income

$6M28.6% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

-34.1%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$203M

Total Liabilities

$11M

Stockholders' Equity

$192M

Cash & Equivalents

$177M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$0	—
Gross Profit	$21M	$0	—
Operating Income	$7M	-$3M	+323.2%
Net Income	$6M	-$3M	+293.8%

Revenue Segments

License and Service

$19M84%

Collaboration

$3M13%

License And Collaboration

$737,0003%